| |
|
Drug Manufacturers - Other News
|
Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
1 hour, 36 minutes ago (PR Newswire)
Orexigen® Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity, today announced that on November 18, 2009 the Compensation Committee of the Company's Board of Directors granted an inducement stock option to purchase 200,000 shares of common stock to Preston Klassen, M.D., its newly appointed Head of the Global Contrave Program.
|
| Intraday
Price Performance | % Change | Market
Cap |
|
Top-Ranked Analysts
|
Provided by StarMine
|
| | |
Locate Industry by Company
|
| Market Capitalization: | 160B | | Price
/ Earnings: | 80.5 | | Price
/ Book: | 9.3 | | Net
Profit Margin (mrq): | 6.9% | | Price
To Free Cash Flow (mrq): | 39.0 | | Return
on Equity: | 6.3% | | Total
Debt / Equity: | 0.0 | | Dividend
Yield: | 0.8% |
|